clinical trial
MSC regenerative therapy
patients
clinical testing
variety of clinical conditions
MSC products
clinical development
clinical expertise
tissue regeneration
harmonized production of MSC
endogenous repair capacity
regenerative effects
visceral Graft
Host Disease
Stem cell regenerative therapies
results of controlled randomized phase
treatment of acute Graft
organ-specific stem
resistant visceral GvHD
treatment of steroid
ethical studies
progenitor cells
efficacy assessment
variety of disorders
organ injury
RETHRIM project
RETHRIM proposal
health technology assessment
Europe-wide placebo
Mesenchymal stromal cells
great promise
additional quality of life
academic infrastructure
functional markers
data
safety
date
Orphan Drug Designation
potency signature
indirect mechanisms
beginning
body
anti-inflammatory properties
commercialization
positive outcome
ability
bone
cartilage
consortium
prediction of response
therapeutic potential
stepping-stone
tissues